微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 57.71% | 6.84% | 2.49% | 56/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 56.31% | 6.86% | 3.52% | 61/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 54.4% | 2.36% | -0.83% | 64/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 54.85% | 26.78% | 1.54% | 69/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.02% | 25.81% | 2.5% | 68/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 52.7% | 26.05% | -0.83% | 74/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 53.14% | 35.39% | 22.83% | 67/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 43.26% | 12.11% | 0.77% | 99/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 42.93% | 8.94% | 2.7% | 97/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 41.81% | 9.54% | 6.52% | 100/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 39.25% | -3.04% | 1.7% | 100/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 38.59% | -13.2% | -2.08% | 105/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 39.41% | -12.58% | 3.27% | 100/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 38.17% | -12.87% | -5.72% | 105/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 40.48% | -9.16% | -8.96% | 94/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 44.46% | -6.62% | -1.38% | 91/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 45.08% | -6.77% | 2.93% | 81/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 43.8% | -3.81% | -1.7% | 87/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 44.56% | -10.04% | -6.41% | 77/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 47.61% | -0.53% | -1.54% | 84/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 48.36% | 0.45% | 6.19% | 72/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 45.54% | 3.93% | -8.07% | 85/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 49.53% | 6.68% | 3.48% | 66/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 47.87% | -2.1% | -0.57% | 83/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 48.14% | -0.24% | 9.87% | 64/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.82% | -5.6% | -5.64% | 73/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 46.43% | 1.89% | -5.03% | 65/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 48.89% | -5.56% | 1.32% | 74/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.26% | -6.86% | 3.97% | 59/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 46.41% | -9.82% | 1.85% | 63/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 45.57% | -9.21% | -11.97% | 61/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 51.77% | -19.99% | -0.08% | 61/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 51.81% | -19.38% | 0.66% | 44/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 51.47% | -18.39% | 2.54% | 42/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 50.19% | -18.14% | -22.42% | 39/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 64.7% | -3.7% | 0.68% | 24/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 64.27% | -3.83% | 1.9% | 19/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 63.07% | -3.94% | 2.86% | 22/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 61.32% | 3.83% | -8.74% | 19/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 67.19% | 14.47% | 0.55% | 16/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 66.83% | 21.9% | 1.79% | 14/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 65.65% | 29.25% | 11.17% | 15/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 59.06% | 29.33% | 0.61% | 19/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |